Mechanism of Jiedu Prescription in Hepatocellular Carcinoma: Integrating Network Pharmacology and Experimental Validation.

ABSTRACT:

Purpose

Hepatocellular carcinoma (HCC) poses a significant global health burden with limited therapeutic options. Traditional Chinese medicine (TCM), particularly Yangyin Fuzheng Jiedu Prescription (YFJP), has shown promise in improving patient outcomes, but its mechanisms are poorly understood. This study aimed to elucidate the key components and mechanisms of YFJP in treating HCC using an integrative approach combining network pharmacology, molecular docking, and experimental validation.

Patients and methods

We analyzed data from 1021 HCC patients (481 treated with YFJP and 540 with Western medicine alone) using propensity score matching to minimize bias. Network pharmacology identified key components and targets of YFJP, with a focus on Jiedu Prescription (JDP). Molecular

SUBMITTER: Wu Y 

PROVIDER: S-EPMC12559631 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature